Millennium Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Millennium Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-147,254	Closed	-$190K	–	7858
2021 Q4	$190K	Sell	147,254 -36,475	-20%	-$64.7K	﹤0.01%	5943
2021 Q3	$399K	Sell	183,729 -39,948	-18%	-$86.9K	﹤0.01%	5565
2021 Q2	$611K	Sell	223,677 -139,300	-38%	-$346K	﹤0.01%	5126
2021 Q1	$947K	Buy	362,977 +284,498	+363%	+$805K	﹤0.01%	4268
2020 Q4	$218K	Sell	78,479 -18,245	-19%	-$53.1K	﹤0.01%	4758
2020 Q3	$447	Buy	+96,724	New	+$319K	﹤0.01%	3634
2020 Q1	–	Sell	-10,310	Closed	-$53K	–	4708
2019 Q4	$53K	Buy	10,310 +72	+0.7%	+$399	﹤0.01%	4093
2019 Q3	$66K	Sell	10,238 -6,897	-40%	-$47.6K	﹤0.01%	4018
2019 Q2	$107K	Sell	17,135 -98,340	-85%	-$749K	﹤0.01%	3884
2019 Q1	$1.23M	Buy	115,475 +52,952	+85%	+$527K	﹤0.01%	2740
2018 Q4	$498K	Buy	62,523 +492	+0.8%	+$7.09K	﹤0.01%	2970
2018 Q3	$1.2M	Sell	62,031 -58,217	-48%	-$1.06M	﹤0.01%	2773
2018 Q2	$2.17M	Sell	120,248 -46,116	-28%	-$680K	﹤0.01%	2337
2018 Q1	$1.77M	Buy	166,364 +105,993	+176%	+$1.7M	﹤0.01%	2391
2017 Q4	$2.54M	Buy	+60,371	New	+$2.71M	﹤0.01%	2136
2017 Q3	–	Sell	-20,073	Closed	-$3.39M	–	3979
2017 Q2	$3.72M	Sell	20,073 -70,096	-78%	-$12.3M	0.01%	1703
2017 Q1	$10.8M	Buy	90,169 +36,883	+69%	+$3.87M	0.02%	979
2016 Q4	$5.29M	Sell	53,286 -35,272	-40%	-$3.71M	0.01%	1293
2016 Q3	$9.92M	Buy	88,558 +78,518	+782%	+$9.43M	0.02%	931
2016 Q2	$1.03M	Buy	+10,040	New	+$1M	﹤0.01%	2148
2015 Q3	–	Sell	-9,322	Closed	-$1.52M	–	3827
2015 Q2	$1.52M	Buy	+9,322	New	+$1.58M	﹤0.01%	2069

Other funds holding SIOX

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Millennium Management's SIOX Position: Q1 2022 in Review

Millennium Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2022, closing a stake of 147,254 shares — an estimated $190K sold.

Millennium Management first reported a position in SIOX in Q2 2015 and held it in 21 quarters. The position peaked at $10.8M in Q1 2017. 41 funds tracked by Wall St. Rank hold SIOX as of Q1 2022.

Millennium Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Millennium Management sold 147,254 Sio Gene Therapies Inc. Common Stock shares in Q1 2022, an estimated $190K.
Millennium Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 21 quarters.
Millennium Management's Sio Gene Therapies Inc. Common Stock position peaked at $10.8M in Q1 2017.
41 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2022.

Based on Millennium Management's 13F filing for Q1 2022, filed 16 May 2022.